COMPANY

Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology is utilizing its proprietary scaffold technology in combination with stem cells to develop a temporary implant designed to inhibit IUAs by stimulating endometrial regeneration and healing post-Dilation and Curettage procedures. From company website Source · Oct 12, 2026

Keywords: implant Esophageal Diseases

Location: Holliston, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $2.84M (Form D filed Sep 14, 2026); +1 other Form D filing in the last 12 months. SEC Form D 0001437749-26-030242 (Sep 14, 2026)
Evidence (2 events)
- Sep 14, 2026 · SEC Form D 0001437749-26-030242
  Name of Issuer: Harvard Apparatus Regenerative Technology, Inc.; CIK: 1563665; Address: Holliston, MA; Submission type: D; Filing date: 2026-09-14; Industry Group: Biotechnology; Date of First Sale: 2026-09-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 2838911; Federal exemptions: 06b
- Jan 6, 2026 · SEC Form D 0001437749-26-000454
  Name of Issuer: Harvard Apparatus Regenerative Technology, Inc.; CIK: 1563665; Address: Holliston, MA; Submission type: D; Filing date: 2026-01-06; Industry Group: Biotechnology; Date of First Sale: 2025-12-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 700000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jul 13, 2023 Trial start Phase 1: Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement source ↗

Upcoming milestones

May 18, 2029 (ESTIMATED) · Phase 1 · Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement · NCT05877300

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT05877300	Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement	Phase 1	Recruiting	Jul 13, 2023	May 18, 2029 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-09-14 Raise Private raise (SEC Form D): $2.8M sold of $3.0M offered; issuer “Harvard Apparatus Regenerative Technology, Inc.”. Verified from the SEC filing. SEC filing ↗
2026-01-06 Raise Private raise (SEC Form D): $700K sold of $2.0M offered; issuer “Harvard Apparatus Regenerative Technology, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-07-14 Raise Private raise (SEC Form D): $2.0M sold; issuer “Harvard Apparatus Regenerative Technology, Inc.”. Verified from the SEC filing. SEC filing ↗